Bioengineering startup Glympse Bio, Inc., raised $22 million in a Series A funding round co-led by venture capital firms LS Polaris Innovation Fund and ARCH Ventures. In addition, new investors Charles River Ventures, Gilead Sciences, Yonghua Capital, and Inevitable Ventures were joined by existing investors GreatPoint Ventures, Heritage Provider Network, and Rivas Capital. Glympse Bio is a spin-out from the laboratory of Sangeeta Bhatia, M.D., Ph.D., at the Massachusetts Institute of Technology.
The company plans to devote the proceeds of this round to conducting clinical trials for a new platform using bioengineered activity sensors to noninvasively detect human diseases and to monitor drug response. This financing follows an initial $6.6 million seed round in 2015 led by Kiran Mazumdar-Shaw at Biocon India Ltd and Theresia Gouw at Aspect Ventures.